Literature DB >> 32196428

Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review.

Takashi Tanaka1, Ming Yang1, Adam T Froemming1, Alan H Bryce1, Ryota Inai1, Susumu Kanazawa1, Akira Kawashima1.   

Abstract

Relapsing level of prostate-specific antigen (PSA) after initial curative-intent local therapy for organ-confined prostate cancer is often the first sign of recurrence. However, PSA level recurrence does not enable accurate differentiation of locally recurrent tumor from metastatic disease or a combination of both. Metastatic prostate cancer most frequently involves bones and lymph nodes, followed by other organs such as the liver, lung, pleura, adrenal gland, ureter, peritoneum, penis, testis, and meninges. Conventional imaging including CT and bone scintigraphy has long been the standard of care but has limited sensitivity in depicting early local recurrence or metastatic disease. Multiparametric MRI has been shown to be more sensitive in detecting locally recurrent tumor in the prostatectomy bed as well as in situ recurrence in a prostate gland that has been treated with radiation therapy or thermal ablation. In addition, lesions detected with multiparametric MRI may be amenable to targeted biopsy for definitive diagnosis of recurrence. PET/CT or PET/MRI using the U.S. Food and Drug Administration (FDA)-approved tracers carbon 11 choline or fluorine 18 fluciclovine has demonstrated markedly increased sensitivity and specificity for diagnosis of early metastatic disease such as small-volume lymph node metastasis, as have a range of investigational gallium 68 prostate-specific membrane antigen (PSMA) radioactive PET tracers. With recent advances in imaging modalities and techniques, more accurate early detection, localization, and characterization of recurrent prostate cancer have become possible. The authors present a contemporary review of the strengths and limitations of conventional and advanced imaging modalities in evaluation of patients with recurrent prostate cancer and a systematic review of the clinical and imaging features of locally recurrent and metastatic disease.©RSNA, 2020See discussion on this article by Barwick and Castellucci.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32196428     DOI: 10.1148/rg.2020190121

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  5 in total

1.  Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients.

Authors:  Elisa Perry; Arpit Talwar; Sanjana Sharma; Daisy O'Connor; Lih-Ming Wong; Kim Taubman; Tom R Sutherland
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-07       Impact factor: 10.057

2.  Image-guided percutaneous cryo-ablation of peri-urethral unresectable recurrent pelvic malignancy: A case report and brief review.

Authors:  Michael E Nance; Mark R Wakefield; Ambarish P Bhat; Ryan M Davis
Journal:  Radiol Case Rep       Date:  2021-03-22

3.  PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.

Authors:  Cynthia Ménard; Sympascho Young; Katherine Zukotynski; Robert J Hamilton; François Bénard; Steven Yip; Christopher McCabe; Fred Saad; Michael Brundage; Roy Nitulescu; Glenn Bauman
Journal:  BMC Cancer       Date:  2022-03-08       Impact factor: 4.430

4.  Radioisotope-guided laparoscopy: a case report and description of an alternative surgical technique.

Authors:  Rodrigo Nascimento Pinheiro; Anderson Arantes Silvestrini; Gabriela El Haje Lobo Rocha; Heloisa Lima Heller; Camila de Carvalho Gallo Pereira; Rodrigo Guimarães Furtado
Journal:  J Surg Case Rep       Date:  2022-03-22

5.  Pathological predictors of 18 F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.

Authors:  Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Tom R Sutherland
Journal:  BJU Int       Date:  2022-06       Impact factor: 5.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.